Nicox Reveals Positive Phase 3 Results for NCX 470 at AGS Meeting

Nicox SA has announced positive findings from Phase 3 studies of NCX 470 at the 2026 American Glaucoma Society Annual Meeting. These results were shared through two podium presentations and a poster, underscoring NCX 470's efficacy in lowering intraocular pressure (IOP) by up to 10mmHg, meeting the New Drug Application requirements in the U.S. and China.

The Denali trial confirmed NCX 470's non-inferiority to latanoprost, with NCX 470 showing superior IOP reduction at several points. The treatment was well tolerated with a low discontinuation rate. Additional data indicated NCX 470's dual mechanism of action involving the trabecular meshwork and uveoscleral pathways.

The U.S. subgroup trial data echoed these findings, further validating NCX 470's safety profile and consistent IOP reduction. These results highlight the potential of NCX 470 as a significant option for patients with unmet needs in glaucoma treatment.